Alzheimer's disease and related disorders.

[1]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[2]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[3]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[4]  W. S. Clark,et al.  Reduction of psychotic symptoms in patients with lewy body-like symptoms treated with olanzapine , 2000, Neurobiology of Aging.

[5]  C. Lyketsos,et al.  A randomized, placebo-controlled, double-blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer disease: Initial results from the diads study , 2000, Neurobiology of Aging.

[6]  David C. Steffens,et al.  Mental and behavioral disturbances in dementia: Findings from the cache county study on memory in aging , 2000, Neurobiology of Aging.

[7]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[8]  D. Selkoe,et al.  The origins of Alzheimer disease: a is for amyloid. , 2000, JAMA.

[9]  P. Austin,et al.  Use of antidepressants among elderly subjects: trends and contributing factors. , 2000, The American journal of psychiatry.

[10]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[11]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[12]  P. Mcgeer,et al.  Brain inflammation in Alzheimer disease and the therapeutic implications. , 1999, Current pharmaceutical design.

[13]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[14]  S. Asthana,et al.  Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study , 1999, Psychoneuroendocrinology.

[15]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[16]  E. Perry,et al.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.

[17]  M Hingorani,et al.  Patients' and doctors' attitudes to amount of information given after unintended injury during treatment: cross sectional, questionnaire survey , 1999, BMJ.

[18]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[19]  O. Lopez,et al.  Dementia with Lewy bodies , 1998, Neurology.

[20]  H. Sackeim,et al.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.

[21]  Bridget Kelly,et al.  A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. , 1998, Archives of neurology.

[22]  T. Sunderland,et al.  Newer Psychotropic Medication Use in Nursing Home Residents , 1998, Journal of the American Geriatrics Society.

[23]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[24]  A. Schatzberg,et al.  A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. , 1997, JAMA.

[25]  Turan M. Itil,et al.  A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia , 1997 .

[26]  L. Teri,et al.  Behavioral treatment of depression in dementia patients: a controlled clinical trial. , 1997, The journals of gerontology. Series B, Psychological sciences and social sciences.

[27]  L. Schneider,et al.  Meta-Analysis of Controlled Pharmacologic Trials , 1997, International Psychogeriatrics.

[28]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[29]  J. Cummings,et al.  Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. , 1996, The American journal of psychiatry.

[30]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[31]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[32]  B. Rovner,et al.  Factors contributing to nursing home admission because of disruptive behaviour , 1996 .

[33]  E. Peskind,et al.  Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. , 1995, Archives of general psychiatry.

[34]  L. Schneider,et al.  A randomized, placebo‐controlled trial of thiothixene in agitated, demented nursing home patients' , 1995 .

[35]  D. Irving,et al.  Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology , 1995, Neuroscience.

[36]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[37]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[38]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[39]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[40]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[41]  H. Refsum,et al.  A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia , 1992, Acta psychiatrica Scandinavica.

[42]  K. Blennow,et al.  Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease , 1992, Neurobiology of Aging.

[43]  L. Teri,et al.  Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. , 1991, Journal of gerontology.

[44]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[45]  Robert H. Perry,et al.  Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.

[46]  L. Teri,et al.  Functional Status and Cognitive Impairment in Alzheimer's Patients With and Without Depression , 1989, Journal of the American Geriatrics Society.

[47]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[48]  P. Tariot,et al.  Pharmacologic modelling of Alzheimer's disease , 1986, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  L. Jarvik,et al.  About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson) , 1986, Alzheimer disease and associated disorders.

[50]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[51]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[52]  M. Raskind,et al.  Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. , 1982, The American journal of psychiatry.

[53]  D. Murphy,et al.  Effort and cognition in depression. , 1982, Archives of general psychiatry.

[54]  W. Wilson,et al.  Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. , 1982, Journal of clinical psychopharmacology.

[55]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[56]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[57]  R. Kellner,et al.  Thiothixene in the Treatment of Geriatric Patients with Chronic Organic Brain Syndrome * , 1976, Journal of the American Geriatrics Society.

[58]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[59]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[60]  R. Cawley.  MENTAL HEALTH: It's Healthy to be Human. , 1968, British Journal of Psychiatry.

[61]  A. Sugerman,et al.  HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE. , 1964, The American journal of psychiatry.

[62]  W. Dahlstrom,et al.  The value of chemotherapy in senile mental distrubances. Controlled comparison of chlorpromazine, reserpine-pipradrol, and opium. , 1960, JAMA.

[63]  J. Cummings.  Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.

[64]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[65]  Rachelle S. Doody,et al.  DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .

[66]  L. Teri,et al.  Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. , 1989, The American journal of psychiatry.